Histone Deacetylase (HDAC) is an established and validated target for the treatment of
cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone
Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has
summarized the inhibitors, based on their specificity towards different isoforms within this class.
Further various recent United State (US) patents and the HDAC inhibitors, used singly or in
combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors
SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of
Keywords: Histone Deacetylase, cancer, isoform, Romidepsin, US-FDA.
Rights & PermissionsPrintExport